This book covers lymphoproliferative disorders in patients with congenital or acquired immunodeficiencies. Acquired immunodeficiencies are caused by infections with the human immunodeficiency virus or arise following immunosuppressive therapy administered after organ transplantation or to treat connective tissue diseases such as rheumatoid arthritis. It was recently discovered that various diseases or therapeutic modalities that induce a state of immunosuppression may cause virally driven lymphoproliferations. This book summarizes for the first time this group of immunodeficiency-associated lymphoproliferations. Immunosurveillance, Immunodeficiency and Lymphoproliferations.- Clinicopathological Characteristics of Post-Transplant Lymphoproliferative Disorders.- Latrogenic Lymphoproliferative Disorders in Non-Transplantation Settings.- The Role of Kaposi's Sarcoma-Associated Herpesvirus (KSHV/HHV-8) in Lymphoproliferative Diseases.- Dendritic Cells for the Induction of EBV Immunity.- NF-?B Inhibition in EBV-Transformed Lymphoblastoid Cell Lines.- Epstein-Barr Viral Load as a Tool to Diagnose and Monitor Post-Transplant Lymphoproliferative Disease.- The Role of Immunosuppression in Lymphoma.- Indentification of Prognostic Factors in Post-Transplant Lymphoproliferative Disorders.- Methods and Objectives of a Large US Multicenter Case-Control Study of Post-Transplant Lymphoproliferative Disorder in Renal Transplant Patients.- Antiviral Treatment of Epstein-Barr Virus-Associated Lymphoproliferations.- Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease.- Engineered Antibody for Treating Lymphoma.- Treatment of Post-Transplant Lymphomas with Anti-B-Cell Monoclonal Antibodies.- Epstein-Barr Virus (EBV)-Specific Cytotoxic T Lymphocytes for the Prevention and Treatment of EBV-Associated Post-Transplant Lymphomas.- Non-Myeloablative Stem Cell Transplantation for Congenital Immunodeficiencies.- Prognostic Factors in the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma.- Infusional CDE with Rituximab for the Treatment of Human Immunodeficiency Virus-Associated Non-Hodgkin's Lymphoma: Preliminary Results of a Phase I/II Study.
